Advertisement

Biology and Epidemiology of Human Papillomavirus-Related Head and Neck Cancer

  • Alexander Y. Deneka
  • Jeffrey C. Liu
  • Camille C. R. Ragin
Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

Human papillomavirus (HPV) infection is now established as a major causative agent for development of the head and neck cancers. HPV-initiated tumors of the oropharynx have better survival rates than HPV-negative cancers, and this appears likely to be associated with differences in the biology underlying these two diseases. We will discuss the role of HPV-encoded proteins in host infection and carcinogenesis; will review the emerging biology of intratypic variants of HPV, with numerous variants possessing different potential for malignancy; and will suggest areas for the further study. Finally, we will highlight global trends in HPV-associated oropharyngeal head and neck cancer incidence and prevalence rates, with recent data showing a dramatic increase of infection worldwide and differing infection rates in developed and developing nations.

Keywords

Human papillomavirus Oropharyngeal cancers Variants Incidence Mortality 

References

  1. 1.
    Hausen HZ, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol. 1994;48(1):427–47.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983;12(6):418–24.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Gillison ML, Koch WM, Capone RB, Spafford MJ, Westra W, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004;363(9420):1488–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev. 2005;14(2):467–75.CrossRefGoogle Scholar
  6. 6.
    Badaracco G, Venuti A, Morello R, Muller A, Marcante ML. Human papillomavirus in head and neck carcinomas: prevalence, physical status and relationship with clinical/pathological parameters. Anticancer Res. 2000;20(2B):1301–5.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer. 2001;92(11):2875–84.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. Cancer. 2001;92(4):805–13.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer. 2000;89(3):300–4.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982–1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(6):622–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Mork J, Lie AK, Glattre E, Clark S, Hallmans G, Jellum E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn L-J, Quint W, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer. 2011;131(5):1179–86.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Sisk EA, Bradford CR, Jacob A, Yian CH, Staton KM, Tang G, et al. Human papillomavirus infection in “young” versus “old” patients with squamous cell carcinoma of the head and neck. Head Neck. 2000;22(7):649–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Venuti A, Manni V, Morello R, De Marco F, Marzetti F, Marcante ML. Physical state and expression of human papillomavirus in laryngeal carcinoma and surrounding normal mucosa. J Med Virol. 2000;60(4):396–402.PubMedCrossRefGoogle Scholar
  15. 15.
    Vietia D, Liuzzi JP, Avila M, De Guglielmo Z, Prado Y, Correnti M. Human papillomavirus detection in head and neck squamous cell carcinoma. Ecancermedicalscience 2014;8.Google Scholar
  16. 16.
    Dahlstrand HM, Dalianis T. Presence and influence of human papillomaviruses (HPV) in Tonsillar cancer. Adv in Cancer Res. 2005;93:59–89.Google Scholar
  17. 17.
    Klussmann JP, Gültekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162(3):747–53.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    El-Mofty SK, Lu DW. Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients. Am J Surg Pathol. 2003;27(11):1463–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Burk RD, Chen Z, Van Doorslaer K. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics. 2009;12(5–6):281–90.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Van Doorslaer K, Burk RD. Evolution of human papillomavirus carcinogenicity. Adv Virus Res. 2010;77:41–62.Google Scholar
  21. 21.
    Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci. 2009;106(48):20458–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol. 2010;118(1):S12–S7.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    McBride AA, Oliveira JG, McPhillips MG. Partitioning viral genomes in mitosis: same idea, different targets. Cell Cycle. 2006;5(14):1499–502.PubMedCrossRefGoogle Scholar
  24. 24.
    Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer. 2017;123(10):1778–90.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A. 2006;103(5):1522–7.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. Virol J. 2010;7:2.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R. Chimeric L2-based Virus-Like Particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV). PLoS One. 2017;12(1):e0169533.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Berg M, Stenlund A. Functional interactions between papillomavirus E1 and E2 proteins. J Virol. 1997;71(5):3853–63.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Powell MLC, Smith JA, Sowa ME, Harper JW, Iftner T, Stubenrauch F, et al. NCoR1 mediates papillomavirus E8^E2C transcriptional repression. J Virol. 2010;84(9):4451–60.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Paolini F, Curzio G, Melucci E, Terrenato I, Antoniani B, Carosi M, et al. Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions. Eur J Cancer. 2016;58:52–61.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Ma T, Zou N, Lin BY, Chow LT, Harper JW. Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication. Proc Natl Acad Sci. 1999;96(2):382–7.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Lin BY, Ma T, Liu J, Kuo SH, Jin G, Broker TR, et al. HeLa cells are phenotypically limiting in cyclin E/CDK2 for efficient human papillomavirus DNA replication. J Biol Chem. 2000;275(9):6167–74.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Liu JS, Kuo SR, Makhov AM, Cyr DM, Griffith JD, Broker TR, et al. Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication. J Biol Chem. 1998;273(46):30704–12.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Lee D, Sohn H, Kalpana GV, Choe J. Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA. Nature. 1999;399(6735):487–91.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Swindle CS, Engler JA. Association of the human papillomavirus type 11 E1 protein with histone H1. J Virol. 1998;72(3):1994–2001.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Yasugi T, Vidal M, Sakai H, Howley PM, Benson JD. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. J Virol. 1997;71(8):5942–51.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Fradet-Turcotte A, Brault K, Titolo S, Howley PM, Archambault J. Characterization of papillomavirus E1 helicase mutants defective for interaction with the SUMO-conjugating enzyme Ubc9. Virology. 2009;395(2):190–201.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lin BY, Makhov AM, Griffith JD, Broker TR, Chow LT. Chaperone proteins abrogate inhibition of the human papillomavirus (HPV) E1 replicative helicase by the HPV E2 protein. Mol Cell Biol. 2002;22(18):6592–604.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Straub E, Dreer M, Fertey J, Iftner T, Stubenrauch F. The viral E8^E2C repressor limits productive replication of human papillomavirus 16. J Virol. 2013;88(2):937–47.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Kurg R. The Role of E2 Proteins in Papillomavirus DNA Replication. DNA Replication– Current Advances. InTech. 2011;DOI: https://doi.org/10.5772/19609.
  42. 42.
    Straub E, Fertey J, Dreer M, Iftner T, Stubenrauch F. Characterization of the human papillomavirus 16 E8 promoter. J Virol. 2015;89(14):7304–13.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Dreer M, Fertey J, van de Poel S, Straub E, Madlung J, Macek B, et al. Interaction of NCOR/SMRT repressor complexes with papillomavirus E8^E2C proteins inhibits viral replication. PLoS Pathog. 2016;12(4):e1005556.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Stubenrauch F, Zobel T, Iftner T. The E8 domain confers a novel long-distance transcriptional repression activity on the E8^E2C protein of high-risk human papillomavirus type 31. J Virol. 2001;75(9):4139–49.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Fertey J, Hurst J, Straub E, Schenker A, Iftner T, Stubenrauch F. Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein. J Virol. 2010;85(6):2918–26.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Doorbar J, Ely S, Sterling J, McLean C, Crawford L. Specific interaction between HPV-16 E1–E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature. 1991;352(6338):824–7.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Khan J, Davy CE, McIntosh PB, Jackson DJ, Hinz S, Wang Q, et al. Role of calpain in the formation of human papillomavirus type 16 E1^E4 amyloid fibers and reorganization of the Keratin network. J Virol. 2011;85(19):9984–97.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    McIntosh PB, Laskey P, Sullivan K, Davy C, Wang Q, Jackson DJ, et al. E1--E4-mediated keratin phosphorylation and ubiquitylation: a mechanism for keratin depletion in HPV16-infected epithelium. J Cell Sci. 2010;123(Pt 16):2810–22.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kumar A, Yadav IS, Hussain S, Das BC, Bharadwaj M. Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: An in silico approach. Biologicals. 2015;43(5):344–8.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Conrad M, Bubb VJ, Schlegel R. The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol. 1993;67(10):6170–8.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Oetke C, Auvinen E, Pawlita M, Alonso A. Human papillomavirus type 16 E5 protein localizes to the Golgi apparatus but does not grossly affect cellular glycosylation. Arch Virol. 2000;145(10):2183–91.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Um SH, Mundi N, Yoo J, Palma DA, Fung K, MacNeil D, et al. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer. J Clin Virol. 2014;61(1):94–100.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    DiMaio D, Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene. 2001;20(54):7866–73.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Häfner N, Driesch C, Gajda M, Jansen L, Kirchmayr R, Runnebaum IB, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene. 2007;27(11):1610–7.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Bouvard V, Matlashewski G, Gu Z-M, Storey A, Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology. 1994;203(1):73–80.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Crusius K, Rodriguez I, Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes. 2000;20(1):65–9.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Liu C, Lin J, Li L, Zhang Y, Chen W, Cao Z, et al. HPV16 early gene E5 specifically reduces miRNA-196a in cervical cancer cells. Sci Rep. 2015;5:7653.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Auvinen E, Alonso A, Auvinen P. Human papillomavirus type 16 E5 protein colocalizes with the antiapoptotic Bcl-2 protein. Arch Virol. 2004;149(9):1745–59.Google Scholar
  59. 59.
    Ashrafi GH, Brown DR, Fife KH, Campo MS. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res. 2006;120(1–2):208–11.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci. 2001;8(2):206–13.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Zhang B, Li P, Wang E, Brahmi Z, Dunn KW, Blum JS, et al. The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-γ. Virology. 2003;310(1):100–8.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Kotnik Halavaty K, Regan J, Mehta K, Laimins L. Human papillomavirus E5 oncoproteins bind the A4 endoplasmic reticulum protein to regulate proliferative ability upon differentiation. Virology. 2014;452–453:223–30.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Paolini F, Curzio G, Cordeiro MN, Massa S, Mariani L, Pimpinelli F, et al. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. Hum Vaccin Immunother. 2017;13(2):291–7.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Gao Q, Kumar A, Srinivasan S, Singh L, Mukai H, Ono Y, et al. PKN binds and phosphorylates human papillomavirus E6 Oncoprotein. J Biol Chem. 2000;275(20):14824–30.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Massimi P, Shai A, Lambert P, Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene. 2007;27(12):1800–4.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–9.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 2004;18(18):2269–82.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Katzenellenbogen RA, Egelkrout EM, Vliet-Gregg P, Gewin LC, Gafken PR, Galloway DA. NFX1-123 and poly(A) binding proteins synergistically augment activation of telomerase in human papillomavirus type 16 E6-expressing cells. J Virol. 2007;81(8):3786–96.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998;12(13):2061–72.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Tong X, Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci. 1997;94(9):4412–7.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Cavarelli J. Crystal structure of full-length Bovine Papillomavirus oncoprotein E6 in complex with LD1 motif of paxillin at 2.3A resolution. Protein Data Bank, Rutgers University;2011.Google Scholar
  73. 73.
    Srivastava K, Pickard A, McDade S, McCance DJ. p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling. Oncotarget. 2017;8(10):16202–19.Google Scholar
  74. 74.
    Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56(20):4620–4.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci. 1996;93(9):4350–4.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Zhang B, Laribee RN, Klemsz MJ, Roman A. Human papillomavirus type 16 E7 protein increases acetylation of histone H3 in human foreskin keratinocytes. Virology. 2004;329(1):189–98.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 Up-regulates AKT activity through the Retinoblastoma protein. Cancer Res. 2006;66(11):5555–9.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Arroyo M, Bagchi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol. 1993;13(10):6537–46.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol. 1992;66(12):6893–902.PubMedPubMedCentralGoogle Scholar
  80. 80.
    McIntyre MC, Ruesch MN, Laimins LA. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology. 1996;215(1):73–82.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8(13):4099–105.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Phelps WC, Bagchi S, Barnes JA, Raychaudhuri P, Kraus V, Munger K, et al. Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J Virol. 1991;65(12):6922–30.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Hausen HZ. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92(9):690–8.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. JNCI Monographs. 2003;2003(31):3–13.CrossRefGoogle Scholar
  86. 86.
    Sano D, Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016;21(5):819–26.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Ragin CCR, Reshmi SC, Gollin SM. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. Int J Cancer. 2004;110(5):701–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Wentzensen N. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 2004;64(11):3878–84.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, et al. Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer. 2017;140(7):1571–80.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol. 2006;44(5):1755–62.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 2002;102(2):152–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Koskinen WJ, Chen RW, Leivo I, Mäkitie A, Bäck L, Kontio R, et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer. 2003;107(3):401–6.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi S, et al. Molecular analyses and prognostic relevance of HPV in head and neck tumours. Oncology Reports. 2007.Google Scholar
  94. 94.
    Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111(43):15544–9.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Wilting SM, Smeets SJ, Snijders PJF, van Wieringen WN, van de Wiel MA, Meijer GA, et al. Genomic profiling identifies common HPVassociated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genet. 2009;2(1):32.Google Scholar
  96. 96.
    van Houten VMM, Snijders PJF, van den Brekel MWM, Kummer JA, Meijer CJLM, van Leeuwen B, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer. 2001;93(2):232–5.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002;21(10):1510–7.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Ragin CCR, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer. 2006;95(10):1432–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    The Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–82.CrossRefGoogle Scholar
  100. 100.
    Smeets SJ, Braakhuis BJM, Abbas S, Snijders PJF, Ylstra B, van de Wiel MA, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2005;25(17):2558–64.CrossRefGoogle Scholar
  101. 101.
    Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol. 2007;213(3):283–93.PubMedCrossRefGoogle Scholar
  102. 102.
    Slebos RJC, Yi Y, Ely K, Carter JJ, Evjen A, Zhang X, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(3):701–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Bernard H-U, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers E-M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA. Virus taxonomy. London: Elsevier; 2005. p. 239–55.Google Scholar
  105. 105.
    de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10.PubMedCrossRefGoogle Scholar
  106. 106.
    Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol. 2008;83(3):1443–55.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One. 2011;6(5):e20183.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Chen Z, Terai M, Fu L, Herrero R, DeSalle R, Burk RD. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol. 2005;79(11):7014–23.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol. 1993;67(11):6413–23.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou V, et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol. 1993;67(11):6424–31.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997;71(3):2463–72.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS One. 2013;8(8):e72565.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, et al. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol. 2012;86(12):6855–61.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci. 1983;80(12):3812–5.PubMedCrossRefGoogle Scholar
  115. 115.
    Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM. Human papillomavirus 18 genetic variation and cervical cancer risk worldwide. J Virol. 2015;89(20):10680–7.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3(5):1151–7.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomark Prev. 2002;11(4):343–51.Google Scholar
  118. 118.
    Makowsky R, Lhaki P, Wiener HW, Bhatta MP, Cullen M, Johnson DC, et al. Genomic diversity and phylogenetic relationships of human papillomavirus 16 (HPV16) in Nepal. Infect Genet Evol. 2016;46:7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Jackson R, Rosa BA, Lameiras S, Cuninghame S, Bernard J, Floriano WB, et al. Functional variants of human papillomavirus type 16 demonstrate host genome integration and transcriptional alterations corresponding to their unique cancer epidemiology. BMC Genomics. 2016;17(1):851.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. JNCI (Journal of the National Cancer Institute). 2001;93(17):1325–30.CrossRefGoogle Scholar
  121. 121.
    Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez AC, et al. Human papillomavirus type 16 variants and risk of cervical cancer. JNCI (Journal of the National Cancer Institute). 2001;93(4):315–8.CrossRefGoogle Scholar
  122. 122.
    Matsumoto K, Yoshikawa H, Nakagava S, Tang X, Yasugi T, Kawana K, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett. 2000;156(2):159–65.PubMedCrossRefGoogle Scholar
  123. 123.
    Villa LL, Caballero O, Ferenczy A, Sichero L, Rohan T, Franco EL, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol. 2000;81(12):2959–68.PubMedCrossRefGoogle Scholar
  124. 124.
    Xi LF, Critchlow CW, Wheeler CM, Koutsky LA, Galloway DA, Kuypers J, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res. 1998;58(17):3839–44.PubMedGoogle Scholar
  125. 125.
    Xi LF, Koutsky LA, Galloway DA, Kiviat NB, Kuypers J, Hughes JP, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. JNCI (Journal of the National Cancer Institute). 1997;89(11):796–802.CrossRefGoogle Scholar
  126. 126.
    Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomark Prev. 2007;16(1):4–10.CrossRefGoogle Scholar
  127. 127.
    Nicolas-Parraga S, Alemany L, de Sanjose S, Bosch FX, Bravo IG. Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. Int J Cancer. 2017;140(9):2092–100.Google Scholar
  128. 128.
    Mammas IN, Spandidos DA, Sourvinos G. Genomic diversity of human papillomaviruses (HPV) and clinical implications: an overview in adulthood and childhood. Infect Genet Evol. 2014;21:220–6.PubMedCrossRefGoogle Scholar
  129. 129.
    Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol. 1996;70(10):6987–93.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Hang D, Gao L, Sun M, Liu Y, Ke Y. Functional effects of sequence variations in the E6 and E2 genes of human papillomavirus 16 European and Asian variants. J Med Virol. 2014;86(4):618–26.PubMedCrossRefGoogle Scholar
  131. 131.
    De la Cruz-Hernandez E, Garcia-Carranca A, Mohar-Betancourt A, Duenas-Gonzales A, Contreras-Paredes A, Perez-Cardenas E, et al. Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J Gen Virol. 2005;86(9):2459–68.PubMedCrossRefGoogle Scholar
  132. 132.
    Vazquez-Vega S, Sanchez-Suarez LP, Andrade-Cruz R, Castellanos-Juarez E, Contreras-Paredes A, Lizano-Soberon M, et al. Regulation of p14 ARF expression by HPV-18 E6 variants. J Med Virol. 2013;85(7):1215–21.PubMedCrossRefGoogle Scholar
  133. 133.
    Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, et al. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol. 2004;78(11):5934–45.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I, Dueñas-González A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology. 2009;383(1):78–85.PubMedCrossRefGoogle Scholar
  135. 135.
    Kämmer C, Tommasino M, Syrjänen S, Delius H, Hebling U, Warthorst U, et al. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br J Cancer. 2002;86(2):269–73.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    May M, Dong XP, Beyer-Finkler E, Stubenrauch F, Fuchs PG, Pfister H. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J. 1994;13(6):1460–6.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Park JS, Hwang ES, Lee CJ, Kim CJ, Rha JG, Kim SJ, et al. Mutational and functional analysis of HPV-16 URR derived from Korean cervical neoplasia. Gynecol Oncol. 1999;74(1):23–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Rose B, Tattersall M, Thompson C, Steger G, Pfister H, Cossart Y, et al. Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. J Gen Virol. 1998;79(7):1659–63.PubMedCrossRefGoogle Scholar
  139. 139.
    Veress G, Szarka K, Gergely L, Pfister H, Dong XP. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J Gen Virol. 1999;80(4):1035–43.PubMedCrossRefGoogle Scholar
  140. 140.
    Hubert WG. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J Virol. 2005;79(10):5914–22.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Chopjitt P, Pientong C, Bumrungthai S, Kongyingyoes B, Ekalaksananan T. Activities of E6 protein of human papillomavirus 16 Asian variant on miR-21 up-regulation and expression of human immune response genes. Asian Pac J Cancer Prev. 2015;16(9):3961–8.PubMedCrossRefGoogle Scholar
  142. 142.
    Du J, Nordfors C, Näsman A, Sobkowiak M, Romanitan M, Dalianis T, et al. Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden. PLoS One. 2012;7(4):e36239.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Boscolo-Rizzo P, Da Mosto MC, Fuson R, Frayle-Salamanca H, Trevisan R, Del Mistro A. HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract. J Cancer Res Clin Oncol. 2008;135(4):559–66.PubMedCrossRefGoogle Scholar
  144. 144.
    Markowitz Lauri E, Sternberg M, Dunne Eileen F, McQuillan G, Unger Elizabeth R. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003–2004. J Infect Dis. 2009;200(7):1059–67.PubMedCrossRefGoogle Scholar
  145. 145.
    Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. Seroprevalence of 9 human papillomavirus types in the United States, 2005–2006. J Infect Dis. 2016;213(2):191–8.PubMedCrossRefGoogle Scholar
  146. 146.
    Zhang Y, Waterboer T, Pawlita M, Sugar E, Minkoff H, Cranston RD, et al. Human papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection. Cancer Epidemiol. 2016;43:30–4.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Gillison ML, Broutian T, Pickard RKL, Tong Z-Y, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong Z, Xiao W, et al. NHANES 2009–2012 findings: association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res. 2015;75(12):2468–77.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. JNCI (Journal of the National Cancer Institute). 2010;102(21):1653–62.CrossRefGoogle Scholar
  150. 150.
    D’Souza G, Kluz N, Wentz A, Youngfellow R, Griffioen A, Stammer E, et al. Oral human papillomavirus (HPV) infection among unvaccinated high-risk young adults. Cancers. 2014;6(3):1691–704.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Kreimer AR, Pierce Campbell CM, Lin H-Y, Fulp W, Papenfuss MR, Abrahamsen M, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382(9895):877–87.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer. 2013.: Available from: http://globocan.iarc.fr/. Accessed on day/month/year.
  153. 153.
    Howlader NNA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2013. National Cancer Institute Bethesda, MD, https://seer.cancer.gov/csr/1975_2013/. based on November 2015 SEER data submission, posted to the SEER web site. 2016; April.
  154. 154.
    Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2015;33(29):3235–42.CrossRefGoogle Scholar
  156. 156.
    Maritz GS, Mutemwa M. Tobacco smoking: patterns, health consequences for adults, and the long-term health of the offspring. Glob J Health Sci. 2012;4(4):62–75.Google Scholar
  157. 157.
    Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362–6.PubMedCrossRefGoogle Scholar
  158. 158.
    Roberts JC, Li G, Reitzel LR, Wei Q, Sturgis EM. No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis. Clin Cancer Res. 2010;16(20):5019–27.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813–20.PubMedCrossRefGoogle Scholar
  160. 160.
    Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. JNCI J Natl Cancer Inst. 2008;100(6):407–20.PubMedCrossRefGoogle Scholar
  161. 161.
    Mbulawa ZZA, Johnson LF, Marais DJ, Coetzee D, Williamson A-L. Risk factors for oral human papillomavirus in heterosexual couples in an African setting. J Infect. 2014;68(2):185–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Vogt SL, Gravitt PE, Martinson NA, Hoffmann J, D’Souza G. Concordant oral-genital HPV infection in South Africa couples: evidence for transmission. Front Oncol. 2013;3:303.Google Scholar
  163. 163.
    Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, et al. Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol. 2014;181(1):40–53.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomark Prev. 2011;21(1):122–33.CrossRefGoogle Scholar
  165. 165.
    Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis. 2014;20(5):822–8.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46.PubMedCrossRefGoogle Scholar
  167. 167.
    Braakhuis BJM, Snijders PJF, Keune WJH, Meijer CJLM, Ruijter-Schippers HJ, Leemans CR, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. JNCI (Journal of the Natl Cancer Institute). 2004;96(13):998–1006.CrossRefGoogle Scholar
  168. 168.
    Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30(17):2102–11.PubMedCrossRefPubMedCentralGoogle Scholar
  169. 169.
    Chaturvedi AK, D’Souza G, Gillison ML, Katki HA. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. Oral Oncol. 2016;60:61–7.PubMedCrossRefGoogle Scholar
  170. 170.
    Jung AC, Briolat J, Millon R, de Reynies A, Rickman D, Thomas E, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer. 2010;126(8):1882–94.PubMedCrossRefGoogle Scholar
  171. 171.
    Deng Z, Hasegawa M, Kiyuna A, Matayoshi S, Uehara T, Agena S, et al. Viral load, physical status, and E6/E7 mRNA expression of human papillomavirus in head and neck squamous cell carcinoma. Head Neck. 2013;35(6):800–8.PubMedCrossRefGoogle Scholar
  172. 172.
    de Souza DLB, de Camargo Cancela M, Pérez MMB, Curado M-P. Trends in the incidence of oral cavity and oropharyngeal cancers in Spain. Head Neck. 2011;34(5):649–54.PubMedCrossRefGoogle Scholar
  173. 173.
    Forte T, Niu J, Lockwood GA, Bryant HE. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992–2009. Cancer Causes Control. 2012;23(8):1343–8.PubMedCrossRefGoogle Scholar
  174. 174.
    Golas SM. Trends in palatine tonsillar cancer incidence and mortality rates in the United States. Community Dent Oral Epidemiol. 2007;35(2):98–108.PubMedCrossRefGoogle Scholar
  175. 175.
    McGorray SP, Guo Y, Logan H. Trends in incidence of oral and pharyngeal carcinoma in Florida: 1981–2008. J Public Health Dent. 2011;72(1):68–74.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012;39(11):860–7.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Attner P, Du J, Näsman A, Hammarstedt L. Ramqvist Tr, Lindholm J, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 2010;126(12):2879–84.Google Scholar
  178. 178.
    Castellsagué X, Mena M, Alemany L. Epidemiology of HPV-positive tumors in Europe and in the world. In: HPV infection in head and neck cancer. Cham: Springer International Publishing; 2016. p. 27–35.Google Scholar
  179. 179.
    Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    D’Souza G, Zhang HH, D’Souza WD, Meyer RR, Gillison ML. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol. 2010;46(2):100–4.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    Ernster JA, Sciotto CG, O’Brien MM, Finch JL, Robinson LJ, Willson T, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117(12):2115–28.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. JNCI (Journal of the National Cancer Institute). 2008;100(4):261–9.CrossRefGoogle Scholar
  183. 183.
    Kingma DW, Allen RA, Moore W, Caughron SK, Melby M, Gillies EM, et al. HPV genotype distribution in oral and oropharyngeal squamous cell carcinoma using seven in vitro amplification assays. Anticancer Res. 2010;30(12):5099–104.PubMedPubMedCentralGoogle Scholar
  184. 184.
    Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas-Baldwin N, et al. Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 multinational randomized trials. Head Neck. 2016;38(Suppl 1):E1863–9.PubMedCrossRefPubMedCentralGoogle Scholar
  185. 185.
    Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck. 2012;35(5):747–55.PubMedCrossRefPubMedCentralGoogle Scholar
  186. 186.
    Rodrigo JP, Heideman DA, Garcia-Pedrero JM, Fresno MF, Brakenhoff RH, Diaz Molina JP, et al. Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990–2009). Int J Cancer. 2014;134(2):487–92.PubMedCrossRefPubMedCentralGoogle Scholar
  187. 187.
    Brown LM, Check DP, Devesa SS. Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns. Journal of Oncology. 2012;2012:1–10.Google Scholar
  188. 188.
    Cole L, Polfus L, Peters ES. Examining the incidence of human papillomavirus-associated head and neck cancers by race and ethnicity in the U.S., 1995–2005. PLoS One. 2012;7(3):e32657.PubMedCrossRefPubMedCentralGoogle Scholar
  189. 189.
    Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg. 1989;115(5):621–5.PubMedCrossRefPubMedCentralGoogle Scholar
  190. 190.
    Chen R, Sehr P, Waterboer T, Leivo I, Pawlita M, Vaheri A, et al. Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol. 2005;43(3):1408–10.PubMedCrossRefPubMedCentralGoogle Scholar
  191. 191.
    do Sacramento PR, Babeto E, Colombo J, Cabral Ruback MJ, Bonilha JL, Fernandes AM, et al. The prevalence of human papillomavirus in the oropharynx in healthy individuals in a Brazilian population. J Med Virol. 2006;78(5):614–8.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Duray A, Descamps G, Bettonville M, Sirtaine N, Ernoux-Neufcoeur P, Guenin S, et al. High prevalence of high-risk human papillomavirus in palatine tonsils from healthy children and adults. Otolaryngol Head Neck Surg. 2011;145(2):230–5.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Ernster JA, Sciotto CG, O’Brien MM, Robinson LJ, Willson T. Prevalence of oncogenic human papillomavirus 16 and 18 in the palatine tonsils of the general adult population. Arch Otolaryngol Head Neck Surg. 2009;135(6):554.PubMedCrossRefPubMedCentralGoogle Scholar
  194. 194.
    Fukushima K, Ogura H, Watanabe S, Yabe Y, Masuda Y. Human papillomavirus type 16 DNA detected by the polymerase chain reaction in non-cancer tissues of the head and neck. Eur Arch Otorhinolaryngol. 1994;251(2):109–12.Google Scholar
  195. 195.
    Mammas IN, Sourvinos G, Michael C, Spandidos DA. Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children. Pediatr Infect Dis J. 2006;25(12):1158–62.PubMedCrossRefPubMedCentralGoogle Scholar
  196. 196.
    Sisk J, Schweinfurth JM, Wang XT, Chong K. Presence of human papillomavirus DNA in tonsillectomy specimens. Laryngoscope. 2006;116(8):1372–4.PubMedCrossRefPubMedCentralGoogle Scholar
  197. 197.
    Snijders PJF, Cromme FV, Van Brule AJCD, Schrijnemakers HFJ, Snow GB, Meijer CJLM, et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer. 1992;51(6):845–50.PubMedCrossRefPubMedCentralGoogle Scholar
  198. 198.
    Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res (An Official Journal of the American Association for Cancer Research). 2002;8(4):1093–100.Google Scholar
  199. 199.
    Tominaga S, Fukushima K, Nishizaki K, Watanabe S, Masuda Y, Ogura H. Presence of human papillomavirus type 6f in tonsillar condyloma acuminatum and clinically normal tonsillar mucosa. Jpn J Clin Oncol. 1996;26(6):393–7.PubMedCrossRefPubMedCentralGoogle Scholar
  200. 200.
    Watanabe S, Ogura H, Fukushima K, Yabe Y. Comparison of Virapap filter hybridization with polymerase chain reaction and Southern blot hybridization methods for detection of human papillomavirus in tonsillar and pharyngeal cancers. Eur Arch Otorhinolaryngol. 1993;250(2):115–9.Google Scholar
  201. 201.
    Fouret P, Martin F, Flahault A, Saint-Guily JL. Human papillomavirus infection in the malignant and premalignant head and neck epithelium. Diagn Mol Pathol. 1995;4(2):122–7.PubMedCrossRefPubMedCentralGoogle Scholar
  202. 202.
    Frisch M, Biggar RJ. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas. Lancet. 1999;354(9188):1442–3.PubMedCrossRefPubMedCentralGoogle Scholar
  203. 203.
    Rose Ragin CC, Taioli E. Second primary head and neck tumor risk in patients with cervical cancer—SEER data analysis. Head Neck. 2007;30(1):58–66.CrossRefGoogle Scholar
  204. 204.
    Sikora AG, Morris LG, Sturgis EM. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg. 2009;135(4):402.PubMedCrossRefPubMedCentralGoogle Scholar
  205. 205.
    Dahlstrom KR, Burchell AN, Ramanakumar AV, Rodrigues A, Tellier PP, Hanley J, et al. Sexual transmission of oral human papillomavirus infection among men. Cancer Epidemiol Biomark Prev. 2014;23(12):2959–64.CrossRefGoogle Scholar
  206. 206.
    Crawford R, Grignon A-L, Kitson S, Winder DM, Ball SLR, Vaughan K, et al. High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology. BMC Cancer. 2011;11(1):473.Google Scholar
  207. 207.
    Dost F, Ford PJ, Farah CS. Heightened risk of second primary carcinoma of the head and neck following cervical neoplasia. Head Neck. 2013;36(8):1132–7.PubMedCrossRefPubMedCentralGoogle Scholar
  208. 208.
    Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur J Cancer Prev. 2000;9(6):433–7.PubMedCrossRefPubMedCentralGoogle Scholar
  209. 209.
    D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.PubMedCrossRefPubMedCentralGoogle Scholar
  210. 210.
    D’Souza G, Agrawal Y, Halpern J, Bodison S, Gillison Maura L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199(9):1263–9.PubMedCrossRefPubMedCentralGoogle Scholar
  211. 211.
    Pickard RKL, Xiao W, Broutian TR, He X, Gillison ML. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex Transm Dis. 2012;39(7):559–66.PubMedCrossRefGoogle Scholar
  212. 212.
    Dahlstrom KR, Li G, Tortolero-Luna G, Wei Q, Sturgis EM. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck. 2010;33(6):847–55.PubMedCrossRefPubMedCentralGoogle Scholar
  213. 213.
    Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan’gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the international head and neck cancer epidemiology (INHANCE) consortium. Int J Epidemiol. 2009;39(1):166–81.PubMedCrossRefPubMedCentralGoogle Scholar
  214. 214.
    Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(12):1992–8.PubMedCrossRefGoogle Scholar
  215. 215.
    Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2010;94(1):30–5.PubMedCrossRefGoogle Scholar
  216. 216.
    Bossi P, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, et al. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Ann Oncol. 2014;25(3):694–9.PubMedCrossRefPubMedCentralGoogle Scholar
  217. 217.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.PubMedCrossRefPubMedCentralGoogle Scholar
  218. 218.
    Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, et al. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol. 2011;23(7):1832–7.PubMedCrossRefGoogle Scholar
  219. 219.
    Urban D, Corry J, Rischin D. What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer? Cancer. 2014;120(10):1462–70.PubMedCrossRefGoogle Scholar
  220. 220.
    Attner P, Nasman A, Du J, Hammarstedt L, Ramqvist T, Lindholm J, et al. Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer. 2012;131(5):1124–30.PubMedCrossRefGoogle Scholar
  221. 221.
    Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly Cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncology Off J Am Soc Clin Oncol. 2016:JCO2016683300.Google Scholar
  222. 222.
    Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol. 2017;18(6):803–11.PubMedCrossRefGoogle Scholar
  223. 223.
    Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res. 2009;2(9):776–81.CrossRefGoogle Scholar
  224. 224.
    Chernock RD, Zhang Q, El-Mofty SK, Thorstad WL, Lewis JS. Human papillomavirus–related squamous cell carcinoma of the oropharynx. Arch Otolaryngol Head Neck Surg. 2011;137(2):163.PubMedCrossRefGoogle Scholar
  225. 225.
    Worsham MJ, Stephen JK, Mahan M, Chen KM, Schweitzer V, Havard S, et al. HPV improves survival for African Americans with throat cancer. Sci Newsline Med Healthcare. 2012.Google Scholar
  226. 226.
    Worsham MJ, Stephen JK, Chen KM, Mahan M, Schweitzer V, Havard S, et al. Improved survival with HPV among African Americans with oropharyngeal cancer. Clin Cancer Res. 2013;19(9):2486–92.PubMedCrossRefPubMedCentralGoogle Scholar
  227. 227.
    Ragin C, Liu JC, Jones G, Shoyele O, Sowunmi B, Kennett R, et al. Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients. Carcinogenesis. 2016;38(2):218–29.Google Scholar
  228. 228.
    Isayeva T, Xu J, Dai Q, Whitley AC, Bonner J, Nabell L, et al. African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesis. Hum Pathol. 2014;45(2):310–9.PubMedCrossRefPubMedCentralGoogle Scholar
  229. 229.
    Liu JC, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, et al. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head Neck. 2016;38(Suppl 1):E867–72.PubMedCrossRefGoogle Scholar
  230. 230.
    Isayeva T, Xu J, Ragin C, Dai Q, Cooper T, Carroll W, et al. The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways. Mod Pathol (An Official Journal of the United States and Canadian Academy of Pathology, Inc.). 2015;28(5):631–53.CrossRefGoogle Scholar
  231. 231.
    Combes JD, Franceschi S. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2014;50(5):370–9.PubMedCrossRefGoogle Scholar
  232. 232.
    Jayaprakash V, Reid M, Hatton E, Merzianu M, Rigual N, Marshall J, et al. Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985–2010. Oral Oncol. 2011;47(11):1048–54.PubMedCrossRefPubMedCentralGoogle Scholar
  233. 233.
    Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011;17:58–72.PubMedCrossRefGoogle Scholar
  234. 234.
    Hobbs CGL, Sterne JAC, Bailey M, Heyderman RS, Birchall MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol. 2006;31(4):259–66.PubMedCrossRefGoogle Scholar
  235. 235.
    Taberna M, Resteghini C, Swanson B, Pickard RK, Jiang B, Xiao W, et al. Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma. Oral Oncol. 2016;61:55–61.PubMedCrossRefGoogle Scholar
  236. 236.
    Brown LM. Epidemiology of alcohol-associated cancers. Alcohol. 2005;35(3):161–8.PubMedCrossRefGoogle Scholar
  237. 237.
    LaVallee RA, Yi H-Y. Apparent per capita alcohol consumption: national, state, and regional trends, 1977–2009. Surveillance Report #92. National Institute on Alcohol Abuse and Alcoholism Division of Epidemiology and Prevention Research Alcohol Epidemiologic Data System. 2012.Google Scholar
  238. 238.
    Services. UDoHaH. Preventing tobacco use among young people: a report of the surgeon general. . Atlanta, Ga, S Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking on Health. 1994.Google Scholar
  239. 239.
    Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer. 2007;110(7):1429–35.PubMedCrossRefGoogle Scholar
  240. 240.
    Services ALARaP. Trends in tobacco use ref type: electronic citation. 2012.Google Scholar
  241. 241.
    Müller S, Pan Y, Li R, Chi AC. Changing trends in oral squamous cell carcinoma with particular reference to young patients: 1971–2006. The Emory university experience. Head Neck Pathol. 2008;2(2):60–6.PubMedCrossRefPubMedCentralGoogle Scholar
  242. 242.
    Schantz SP, Yu G-P. Head neck cancer incidence trends in young Americans, 1973–1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002;128(3):268.PubMedCrossRefGoogle Scholar
  243. 243.
    Shiboski CH, Schmidt BL, Jordan RCK. Tongue and tonsil carcinoma. Cancer. 2005;103(9):1843–9.PubMedCrossRefGoogle Scholar
  244. 244.
    Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology. 2011;81(1):12–20.PubMedCrossRefPubMedCentralGoogle Scholar
  245. 245.
    Elango KJ, Suresh A, Erode EM, Subhadradevi L, Ravindran HK, Iyer SK, et al. Role of human papilloma virus in oral tongue squamous cell carcinoma. Asian Pac J Cancer Prev. 2011;12(4):889–96.PubMedGoogle Scholar
  246. 246.
    Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, et al. The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer. Cancer. 2017;123(9):1566–75.Google Scholar
  247. 247.
    Chen X, Gao L, Sturgis EM, Liang Z, Zhu Y, Xia X, et al. HPV16 DNA and integration in normal and malignant epithelium: Implications for the etiology of laryngeal squamous cell carcinoma. Ann Oncol. 2017;28(5):1105–10.Google Scholar
  248. 248.
    Duray A, Descamps G, Decaestecker C, Remmelink M, Sirtaine N, Lechien J, et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope. 2012;122(7):1558–65.PubMedCrossRefGoogle Scholar
  249. 249.
    Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012;6(S1):104–20.CrossRefPubMedPubMedCentralGoogle Scholar
  250. 250.
    Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013;49(1):1–8.PubMedCrossRefGoogle Scholar
  251. 251.
    Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis. 2012;207(3):479–88.PubMedCrossRefGoogle Scholar
  252. 252.
    Stephen JK, Chen KM, Shah V, Havard S, Lu M, Schweitzer VP, et al. Human papillomavirus outcomes in an access-to-care laryngeal cancer Cohort. Otolaryngol Head Neck Surg. 2012;146(5):730–8.PubMedCrossRefPubMedCentralGoogle Scholar
  253. 253.
    Wilson DD, Rahimi AS, Saylor DK, Stelow EB, Jameson MJ, Shonka DC, et al. p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(6):556.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Alexander Y. Deneka
    • 1
    • 2
  • Jeffrey C. Liu
    • 3
  • Camille C. R. Ragin
    • 3
    • 4
  1. 1.Molecular Therapeutics ProgramFox Chase Cancer CenterPhiladelphiaUSA
  2. 2.Kazan Federal UniversityKazanRussia
  3. 3.Department of OtolaryngologyLewis Katz School of Medicine at Temple UniversityPhiladelphiaUSA
  4. 4.Cancer Prevention and Control ProgramFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations